Asset: Novel multi-functional recombinant polypeptide with antibacterial, anti-inflammatory and anti-HPV activities
Development Stage: IND enabling stage
Indication: Vaginitis and HPV infection
Key Asset Highlights:
（1）Possesses triple core pharmacological activities including antibacterial, anti-inflammatory and anti-HPV effects, targeting multiple pathogenic mechanisms of female genital tract infectious diseases with a unique multi-dimensional therapeutic logic.
（2）Exerts broad-spectrum bactericidal and inhibitory activity against common pathogenic microorganisms causing vaginitis, effectively eliminating infectious pathogens and improving vaginal microecological disorders.
（3）Significantly suppresses local inflammatory responses, relieving vaginal mucosal congestion, edema and inflammatory exudation, and rapidly ameliorating clinical symptoms of vaginitis.
（4）Demonstrates potent inhibitory activity against HPV, interfering with viral replication and infection progression, providing an innovative intervention approach for persistent HPV infection.
（5）Features excellent biocompatibility and localized therapeutic properties with minimal systemic exposure, maintaining a favorable safety profile and supporting long-term recurrent infection management.
（6）Protected by a solid and comprehensive intellectual property portfolio, ensuring stable and exclusive global development and commercialization rights for genital tract infection and HPV-related indications.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
